Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.
作者信息
Honore Patrick M, Barreto Gutierrez Leonel, Kugener Luc, Redant Sebastien, Attou Rachid, Gallerani Andrea, De Bels David
机构信息
ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium.
出版信息
Crit Care. 2020 Oct 9;24(1):603. doi: 10.1186/s13054-020-03294-7.
Abstract
摘要
相似文献
1
Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.英夫利昔单抗可将新冠肺炎危重症患者的死亡率从35%降至14%：或许有一些潜在混杂因素需要考虑。
Crit Care. 2020 Oct 9;24(1):603. doi: 10.1186/s13054-020-03294-7.
2
To immunosuppress: whom, when and how? That is the question with COVID-19.进行免疫抑制：对象是谁、何时进行以及如何进行？这就是新冠病毒病面临的问题。
Ann Rheum Dis. 2020 Sep;79(9):1129-1131. doi: 10.1136/annrheumdis-2020-218694. Epub 2020 Aug 4.
3
Cytokine storm syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子风暴综合征
Autoimmun Rev. 2020 Jul;19(7):102562. doi: 10.1016/j.autrev.2020.102562. Epub 2020 May 3.
4
Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?针对危重症 COVID-19 患者的细胞因子风暴综合征，血液净化疗法是否有作用？
Ren Fail. 2020 Nov;42(1):483-488. doi: 10.1080/0886022X.2020.1764369.
5
Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?COVID-19 与抗 MDA5 综合征的相似之处：我们能从中吸取哪些经验以改善治疗？
Eur Respir J. 2020 Sep 24;56(3). doi: 10.1183/13993003.01618-2020. Print 2020 Sep.
6
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?托珠单抗治疗新型冠状病毒肺炎细胞因子风暴综合征：念珠菌血症风险增加？
Autoimmun Rev. 2020 Jul;19(7):102564. doi: 10.1016/j.autrev.2020.102564. Epub 2020 May 5.
7
Is the HScore useful in COVID-19?HScore在新冠病毒疾病（COVID-19）中有用吗？
Lancet. 2020 May 16;395(10236):e83. doi: 10.1016/S0140-6736(20)31057-6. Epub 2020 May 5.
8
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'.对《免疫抑制对危重症COVID-19患者死亡率的影响》的回应
Br J Haematol. 2020 Nov;191(3):505-506. doi: 10.1111/bjh.17110. Epub 2020 Oct 26.
9
Impactful Policy Action to Reduce Drug Costs in Managing Critically Ill Patients with COVID-19.降低新冠肺炎重症患者治疗药物成本的有效政策行动
Mayo Clin Proc. 2020 Aug;95(8):1808-1809. doi: 10.1016/j.mayocp.2020.06.042. Epub 2020 Jun 30.
10
Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19).新冠肺炎危重症患者的静脉血栓栓塞症。
JAMA Netw Open. 2020 May 1;3(5):e2010478. doi: 10.1001/jamanetworkopen.2020.10478.
引用本文的文献
1
COVID-19: A novel holistic systems biology approach to predict its molecular mechanisms (in vitro) and repurpose drugs.COVID-19：一种预测其分子机制（体外）和重新利用药物的新型整体系统生物学方法。
Daru. 2023 Dec;31(2):155-171. doi: 10.1007/s40199-023-00471-1. Epub 2023 Aug 19.
2
SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report.两剂英夫利昔单抗治疗溃疡性结肠炎致 COVID-19 肺炎患者：病例报告
Medicine (Baltimore). 2022 Jan 28;101(4):e28722. doi: 10.1097/MD.0000000000028722.
3
The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients.实体器官移植受者中 SARS-CoV-2 感染和疫苗的免疫学
Viruses. 2021 Sep 20;13(9):1879. doi: 10.3390/v13091879.
本文引用的文献
1
Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series.英夫利昔单抗治疗重症新型冠状病毒肺炎所致细胞因子风暴综合征伴器官衰竭——警示性病例系列
Crit Care. 2020 Jul 17;24(1):444. doi: 10.1186/s13054-020-03158-0.
2
Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.噬血细胞性淋巴组织细胞增生症：COVID-19 大流行引发的综述。
Rheumatol Int. 2021 Jan;41(1):7-18. doi: 10.1007/s00296-020-04636-y. Epub 2020 Jun 25.
3
Precision medicine for COVID-19: a call for better clinical trials.针对2019冠状病毒病的精准医学：呼吁开展更好的临床试验。
Crit Care. 2020 Jun 2;24(1):282. doi: 10.1186/s13054-020-03002-5.
4
Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.严重 COVID-19 合并噬血细胞性淋巴组织细胞增生症患者对阿那白滞素的良好反应。
Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1. doi: 10.1016/j.chom.2020.05.007. Epub 2020 May 14.
5
Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.SARS-CoV-2 感染患者外周血淋巴细胞反应和细胞因子谱的纵向特征。
EBioMedicine. 2020 May;55:102763. doi: 10.1016/j.ebiom.2020.102763. Epub 2020 Apr 18.
6
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
7
The Use of Ferritin to Identify Critically Ill Patients With Secondary Hemophagocytic Lymphohistiocytosis.铁蛋白在继发性噬血细胞性淋巴组织细胞增生症危重症患者中的应用。
Crit Care Med. 2016 Nov;44(11):e1045-e1053. doi: 10.1097/CCM.0000000000001878.
Zotero 插件